From DCAT Value Chain Insights (VCI)
Bristol-Myers Squibb (BMS) has appointed Fouad Namouni, MD, as oncology development head, effective on July 25, 2016. Dr. Namouni will be responsible for leading the execution of a development strategy for the company’s oncology pipeline from the early development stage through commercialization.
Dr. Namouni most recently served as head of BMS’ medical organization, and, prior to that, was the development lead for the company’s immuno-oncology drugs, Yervoy and Opdivo. Dr. Namouni joined BMS in France in 1999 as life-cycle manager for Taxol and has held positions of increasing responsibility in R&D since. He moved to the United States in September 2006 and became responsible for the development of Erbitux. Earlier in his career, Dr. Namouni was a pediatric oncologist at Institut Curie in Paris where his focus was clinical research for the treatment of pediatric tumors.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription